Cover ImageSALE


Global Antibody Conjugates Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 355998
出版日期 內容資訊 英文 75 Pages
Back to Top
抗體複合體藥物的全球市場:2016∼2020年 Global Antibody Conjugates Drugs Market 2016-2020
出版日期: 2016年03月31日 內容資訊: 英文 75 Pages



第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 抗體藥物複合體概要

  • 抗體
  • 單株抗體治療藥的發展
  • 複合體單株抗體
  • 歷史
  • 抗體藥物複合體的主要組成
  • 新一代抗體藥物複合體
  • 優點
  • 課題
  • 抗體藥物複合體製造的外包
  • 抗體藥物複合體的登場
  • 現在上市的抗體藥物複合體

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各單株抗體市場區隔

第9章 抗體藥物複合體所採用的各技術市場區隔

第10章 各地區市場區隔

第11章 推動市場的要素

  • 堅固的後期開發平台
  • 癌症的罹患率上升
  • 抗體複合體的需求擴大
  • 償付政策

第12章 促進要素的影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 主要消息
  • F. Hoffmann-La Roche
  • Seattle Genetics
  • 武田藥品工業株式會社

第17章 附錄

第18章 關於Technavio


Product Code: IRTNTR8911

About Antibody Drug Conjugates

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.

Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Technavio's analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche AG
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company

Other Prominent Vendors

  • AbbVie
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • ALMAC Group
  • Ambrx
  • Astellas Pharma
  • AstraZeneca
  • Bayer HealthCare
  • Celldex Therapeutics
  • Daiichi Sankyo
  • Endo Pharmaceuticals
  • Esperance Pharmaceuticals
  • Formation Biologics
  • Genmab
  • GlaxoSmithKline
  • Immunogen
  • Kairos Therapeutics
  • MedImmune
  • Mersana Therapeutics
  • Novartis
  • Oxford Biotherapeutics
  • Pfizer
  • Stemcentrx
  • Synthon Biopharmaceuticals
  • Zymeworks

Market driver

  • Robust late-stage pipeline
  • For a full, detailed list, view our report

Market challenge

  • High developmental costs
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of ADCs

  • Antibodies
  • Evolution of mAb therapeutics
  • Conjugated mAbs
  • History
  • Key components in ADCs
  • Next-generation ADCs
  • Advantages
  • Challenges
  • Outsourcing of ADCs manufacturing
  • Emergence of ADCs
  • Current marketed ADCs
  • PART 06: Pipeline portfolio
  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by MOA

  • IgG1 antibodies
  • HER2 antibodies

PART 09: Market segmentation by technologies used in ADCs

  • Seattle Genetics (SGEN) technology
  • ImmunoGen (IMGN) technology
  • Immunomedics (IMMU) technology

PART 10: Geographical segmentation

PART 11: Market drivers

  • Robust late-stage pipeline
  • Rising prevalence of cancers
  • Increase in demand for antibody conjugates
  • Reimbursement policies

PART 12: Impact of drivers

PART 13: Market challenges

  • High developmental costs
  • Stringent regulations
  • Risk of side effects

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Strategic alliances
  • Increased outsourcing of drug development
  • Emergence of targeted and combination therapies

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • F. Hoffmann-La Roche
  • Seattle Genetics
  • Takeda Pharmaceuticals

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Comparison of small molecule and mAbs
  • Exhibit 03: Preparation of mAbs
  • Exhibit 04: Timeline of ADCs
  • Exhibit 05: Key components
  • Exhibit 06: Components of next-generation ADCs
  • Exhibit 07: Advantages of ADCs
  • Exhibit 08: Emergence of ADCs
  • Exhibit 09: Marked ADCs products
  • Exhibit 10: Pipeline portfolio of ADCs
  • Exhibit 11: Pipeline share of ADCs
  • Exhibit 12: Market share of ADCs in clinical development
  • Exhibit 13: Few target antigens for ADCs in clinical development
  • Exhibit 14: Top five companies share in ADC pipeline
  • Exhibit 15: Global ADCs market 2015-2020 ($ billions)
  • Exhibit 16: Five forces analysis
  • Exhibit 17: Global ADCs market segmentation by MOA
  • Exhibit 18: Components in IMGN technology
  • Exhibit 19: Share of ADCs technologies
  • Exhibit 20: Global ADCs market by geography 2015
  • Exhibit 21: ADCs market in Americas 2015
  • Exhibit 22: ADCs market in Europe 2015
  • Exhibit 23: ADCs market in Japan 2015
  • Exhibit 24: Global incidence of cancer 2015 and 2020
  • Exhibit 25: Impact of drivers
  • Exhibit 26: Impact of drivers and challenges
  • Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
  • Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015
  • Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
  • Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
  • Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
  • Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
  • Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
  • Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
  • Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products
  • Exhibit 36: F. Hoffmann La-Roche: Key takeaways
  • Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
  • Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline
  • Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs
  • Exhibit 40: Seattle Genetics: ADC collaborations
  • Exhibit 41: Seattle Genetics: Key takeaways
  • Exhibit 42: Takeda: Business segmentation by revenue 2015
  • Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
  • Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
  • Exhibit 45: Takeda Pharmaceuticals: Key takeaways
Back to Top